NCT05232916Phase 3Recruiting

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Study sponsor: Greenwich LifeSciences, Inc. · GLSI

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2031-12Estimated
Enrollment · participants2250Estimated
Source updated2026-08-06Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Planned enrollment increased by 1500 participants

Before: 750 participants (planned). After: 2250 participants (planned).

Primary completion date changed

Before: Dec 2026. After: Dec 2031.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview